At a late-breaking session of the 72nd annual meeting of the American Academy of Dermatology (AAD) in March, Galderma Laboratories, L.P. announced that in two separate trials, its investigational drug ivermectin 1% had shown positive results for the treatment of papulopustular, or inflammatory, rosacea. These pivotal studies were Phase 3 randomized, double-blind, 12-week vehicle controlled parallel group studies that involved 910 subjects who applied ivermectin 1% cream once daily for 12 weeks. The studies demonstrate that ivermectin is safe and effective with the onset of treatment effect starting at four weeks.